Optomed Oyj - Inside information

Inside information, profit warning: Optomed decreases its full year outlook

Optomed PlcInside Information25 September 2024 at 20.00, Helsinki

Inside information, profit warning: Optomed decreases its full year outlook

Optomed decreases its full year 2024 outlook. The Company now expects its full
year 2024 revenue to decrease from 2023. In the Software Segment, certain key
deliveries have been postponed until 2025, and in the Devices Segment, the
traditional distributor and OEM sales have been slower than estimated earlier.
Optomed estimates that in the US revenue will grow strongly and grow in China
compared to 2023. The Q3-2023 comparison period was positively affected by a
delivery to Valencia, Spain worth approximately EUR 800,000.

The sales of Optomed Aurora AEYE have started, and the service has received
positive feedback from paying customers. However, the Optomed Aurora AEYE
recurring revenue service will not have a material effect on the Company's full
year 2024 revenue outlook.

The updated outlook for 2024:

“Optomed expects its full year 2024 revenue to decrease from 2023.”

Previously outlook (announced 15 February 2024):

“Optomed expects its full year 2024 revenue to grow compared to 2023.”

Optomed utilizes seven thresholds in relation to its revenue guidance: in
Optomed's outlook, the revenue may “grow/decrease very strongly”, “grow/decrease
strongly”, “grow/decrease” or “stay on the same level”. The Company has set
fixed internal percentages to reflect each threshold.
Optomed will publish the Interim Report for January-September 2024 on 7 November
2024.
Optomed Plc

Further enquiries

Juho Himberg, CEO, juho.himberg@optomed.com

Optomed in Brief

Optomed is a Finnish medical technology company and a leading manufacturer of
handheld fundus cameras and screening software. Optomed combines handheld fundus
cameras with software and artificial intelligence with the aim to transform the
diagnostic process of various diseases, such as rapidly increasing diabetic
retinopathy. Optomed has offices in Finland, the US and China and the company's
products are sold via various sales channels in over 60 countries globally

www.optomed.com